Objective To describe a cluster of symptomatic intravitreal silicone oil (SiO) droplets following intravitreal injections (IVIs) and assess the effect of switching to a SiO-free syringe. Methods and analysis Observational quality registry study of patients receiving IVI at a large Norwegian ophthalmology centre between April 2018 (start of cluster) and November 2019 (1 year after switching to SiO-free syringes). At onset, anti-vascular endothelial growth factor drugs were administered using SiO-containing insulin syringes. From November 2018, SiO-free syringes were implemented. Spontaneously reported symptomatic SiO cases were confirmed by slit-lamp examination. A follow-up interview was performed after 1 year, assessing visual complaints. The prevalence of non-symptomatic cases was assessed in a sample of 50 eyes from 50 consecutive IVI patients. Results Among 13 429 IVIs, 50 eyes of 46 patients (29 women) with symptomatic intravitreal SiO droplets were identified. Forty-one patients reported floaters at regular appointments, whereas five patients contacted the department regarding symptoms between scheduled appointments. After 1 year, 34 patients (79%) still experienced floaters, 21 (49%) reported reduced symptoms and 3 (7%) reported worsened symptoms. Eighteen patients (42%) reported being bothered, and eight (18.6%) reported that their lives were negatively affected by the floaters. Among 50 non-symptomatic eyes that had received IVI during the same period, intravitreal SiO was found in 34 (68%). No cases of symptomatic intravitreal SiO droplets were identified after switching to SiO-free syringes. Conclusion Symptomatic intravitreal SiO following IVI can cause significant and prolonged distress for affected patients. It can be avoided by using SiO-free syringes. Data are available upon request.

中文翻译：

---

玻璃体内注射后出现症状的硅油滴簇：一项为期 1 年的观察性研究

目的 描述玻璃体内注射 (IVI) 后的一组有症状的玻璃体内硅油 (SiO) 液滴，并评估改用无 SiO2 注射器的效果。方法和分析 2018 年 4 月（集群开始）至 2019 年 11 月（改用无 SiO2 注射器后 1 年）期间在挪威一家大型眼科中心接受 IVI 的患者的观察质量登记研究。开始时，使用含 SiO2 的胰岛素注射器给予抗血管内皮生长因子药物。从 2018 年 11 月开始，实施了不含 SiO2 的注射器。通过裂隙灯检查证实了自发报告的有症状的 SiO 病例。1 年后进行了随访，评估视觉不适。在来自 50 名连续 IVI 患者的 50 只眼睛样本中评估了无症状病例的患病率。结果 在 13 429 例 IVI 中，46 名患者（29 名女性）的 50 只眼被识别出有症状的玻璃体内 SiO 液滴。41 名患者在定期约会时报告了漂浮物，而 5 名患者在预定约会之间就症状联系了该部门。1 年后，34 名患者 (79%) 仍出现飞蚊症，21 名 (49%) 报告症状减轻，3 名 (7%) 报告症状恶化。18 名患者 (42%) 报告受到困扰，8 名 (18.6%) 报告说他们的生活受到了漂浮物的负面影响。同期接受IVI的50只无症状眼中，34只（68%）发现玻璃体内SiO。改用无 SiO2 注射器后，未发现有症状的玻璃体内 SiO2 液滴。结论 IVI 后有症状的玻璃体内 SiO 会对受影响的患者造成显着和长期的痛苦。使用不含 SiO 的注射器可以避免这种情况。数据可应要求提供。